Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/14/19 | SC TO-I | Issuer tender offer statement |
|
57 | |
| 05/10/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 05/10/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 05/09/19 | 8-K | Current report filing |
|
9 | |
| 05/02/19 | 8-K | Current report filing |
|
23 | |
| 04/22/19 | DEF 14A | Definitive proxy statements |
|
37 | |
| 04/17/19 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
57 | |
| 04/17/19 | 8-K | Current report filing |
|
5 | |
| 04/10/19 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
37 | |
| 04/09/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
46 |
